FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549
-------------	------------

Washington,	D.C.	20549	

STATEMENT OF STIANOES IN BENEFICIAL SWINLINGTIII
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number: 3235-028 Estimated average burden										
	hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  SBLENDORIO GLENN						2. Issuer Name and Ticker or Trading Symbol  IVERIC bio, Inc. [ ISEE ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
					111									X Direc	or		10% Ov	/ner	
(Last)	`	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 06/22/2023							X Officer (give title below) Other (special below)  Chief Executive Officer			pecify			
C/O IVERIC BIO, INC. 8 SYLVAN WAY				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)					-									′	filed by On	e Rep	orting Perso	n	
PARSIP	PANY N	J	07054										Form filed by More than One Reporting Person						
(City) (State) (Zip)					Ru	Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - No	n-Deri	vative	Sec	curit	ies Ac	quired,	Dis	posed o	of, or Be	neficia	lly Owne	d				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Date)					Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				Benefi Owned	ties cially Following	es Formally (D) (Following (I) (I		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price		ed ction(s) 3 and 4)			(Instr. 4)		
Common Stock 06/22/2					/2023				M		11,08	4 A	\$13.2	13.216 239,275			D		
		Т	able II -									, or Ben ble secu		y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,	4. Transac Code (li 8)		on of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$13.216	06/22/2023			M			11,084	(1)		07/08/2023	Common Stock	11,084	\$0	0		D		

## **Explanation of Responses:**

1. This option was granted on July 9, 2013 under the Registrant's 2007 Stock Incentive Plan and vested in monthly increments for a period of 36 months from the date of the grant.

## Remarks:

/s/ David Carroll, as Attorneyin-Fact for Glenn P. Sblendorio

06/26/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.